Prokinetic Therapy for Gastroparesis: Metoclopramide vs Domperidone

Efficacy and Indication

Both metoclopramide and domperidone are D₂‑dopamine receptor antagonists that improve nausea, vomiting, and early satiety in patients with gastroparesis. 1, 2
Treatment response is typically evaluated after 4–8 weeks to decide whether to continue therapy. 1, 3
The 2025 American Gastroenterological Association (AGA) guidelines do not recommend either agent as first‑line therapy for gastroparesis. 1, 2

Both agents can prolong the QT interval and may precipitate cardiac arrhythmias; baseline and follow‑up ECG monitoring of QTc is required. 2, 4

Metoclopramide carries an FDA black‑box warning for extrapyramidal reactions—including acute dystonia, drug‑induced parkinsonism, akathisia, and potentially irreversible tardive dyskinesia. 1, 5, 6
The FDA advises that metoclopramide treatment should not exceed 12 weeks because of tardive dyskinesia risk. 5, 7
Domperidone has minimal central nervous system side effects and is preferred for patients who have experienced neurologic adverse effects with metoclopramide. 1, 2
Domperidone is the drug of choice for patients with pre‑existing movement disorders (e.g., Parkinson’s disease). 1, 2

Metoclopramide is FDA‑approved for the treatment of gastroparesis in the United States. 5, 7
Domperidone is not FDA‑approved in the United States; it can be used only through an expanded‑access investigational new drug (IND) application. 1, 2, 4
The current domperidone supplier for the FDA IND program is exiting the market, making the drug’s availability extremely limited. 1, 2

Metoclopramide: monitor for movement disorders at 4–8 weeks; consider drug holidays of 1–4 weeks every 8–12 weeks to improve tolerability. 1, 3, 8
Domperidone: obtain baseline and periodic serum potassium and magnesium levels and perform ECG QTc monitoring throughout therapy. 2, 4, 9

Metoclopramide: 5–10 mg orally before meals (dose may be increased to 10 mg); intranasal formulation 15 mg before meals and at bedtime. 3, 8, 7
Domperidone: 10–20 mg three times daily; doses >10 mg three times daily are discouraged because of increased QT‑prolongation risk. 7

Do not continue metoclopramide beyond 12 weeks without a risk‑benefit reassessment because of tardive dyskinesia risk. 5
Do not assume domperidone is readily available in the United States; it requires special FDA authorization. 1, 2
Obtain baseline ECG and electrolyte panels before initiating either agent. 2, 4
Elderly patients are at higher risk for adverse events with metoclopramide and should be monitored more closely. 8